Skip to content

Public FDA record

Z-0672-05: Software written for a specific automated microtiter plate instrument, Bio-Tek ELx800 reader for use with

Recall record Z-0672-05 for Diasorin Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0672-05
Company in FDA record
Diasorin Inc.
FDA classification date
Apr 6, 2005
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

An error in the Bio-Tek ELx800 microplate reader programming specifications for the ENA screen Assay exists in that an equivocal (borderline) zone is missing.

Source facts

Action
Customers were sent a notification letter informing customers of an error in the Bio-Tek ELx800 programming specifications. Customers were asked to repeat testing for historical runs for RSLT (S/CO) that read from 0.95 to 1.0. A response form is asked to be faxed back to DiaSorin.
Initiated
2004-04-20
Root cause
Other
Terminated
2006-07-22
Distribution
CT, FL, NY, WA, TX, AR, TN, CANADA
Recall number
Z-0672-05
Recall status
Terminated
CDRH record ID
36809
FDA classified
2005-04-06
Recall event number
30920

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗